Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)
Nizar J. Bahlis, Shambavi Richard, Darrell White, Sebastian Grosicki, Christine Chen, Sosana Delimpasi, Heather J. Sutherland, Zvenyslava Maslyak, Michaël Sébag, Maria Gavriatopoulou, Suzanne Lentzsch, Ajai Chari, Maryana Simonova, Ivan Špıčka, Iryna Kriachok, Meletios A Dimopoulos, Halyna Pylypenko, Holger W. Auner, Xavier Leleu, Ganna Usenko, Roman Hájek, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P. Venner, Mamta Garg, Don A. Stevens, Hang Quach, Sundar Jagannath, Philippe Moreau, Moshe Levy, Ashraf Badros, Larry D. Anderson, Thierry Façon, María‐Victoria Mateos, Michèle Cavo, Andrew DeCastro, Yi Chai, Dane R. Van Domelen, Moran Mishal, Ohad S. Bentur, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Paul G. Richardson (2021). Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd). , 138(Supplement 1), DOI: https://doi.org/10.1182/blood-2021-146324.
Article32 days agoSelinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
Shambavi Richard, Ajai Chari, Sosana Delimpasi, Maryana Simonova, Ivan Špıčka, Luděk Pour, Iryna Kriachok, Meletios A Dimopoulos, Halyna Pylypenko, Holger W. Auner, Xavier Leleu, Ganna Usenko, Roman Hájek, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P. Venner, Mamta Garg, Don A. Stevens, Hang Quach, Sundar Jagannath, Philippe Moreau, Moshe Levy, Ashraf Badros, Larry D. Anderson, Nizar J. Bahlis, Thierry Façon, María‐Victoria Mateos, Michèle Cavo, Hua Chang, Yosef Landesman, Yi Chai, Melina Arazy, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Sebastian Grosicki, Paul G. Richardson (2021). Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. , 96(9), DOI: https://doi.org/10.1002/ajh.26261.
Article32 days agoOnce Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study
Shambavi Richard, Ajai Chari, Sosana Delimpasi, Maryana Simonova, Ivan Špıčka, Luděk Pour, Irina Kryachok, Meletios A Dimopoulos, Halyna Pylypenko, Holger W. Auner, Xavier Leleu, Vadim Doronin, Ganna Usenko, Roman Hájek, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P. Venner, Mamta Garg, Don A. Stevens, Hang Quach, Sundar Jagannath, Philippe Moreau, Moshe Levy, Ashraf Badros, Larry D. Anderson, Nizar J. Bahlis, Thierry Façon, María‐Victoria Mateos, Michèle Cavo, Hua Chang, Yosef Landesman, Anita Joshi, Yi Chai, Melina Arazy, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Sebastian Grosicki, Paul G. Richardson (2020). Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study. , 136(Supplement 1), DOI: https://doi.org/10.1182/blood-2020-137154.
Article32 days ago